GLP-1 peptide analogues CNTO3649 and exendin-4 reduced VLDL production and hepatic steatosis after 4 weeks of treatment in high fat diet-fed APOE*3-Leiden transgenic mice, a mouse model with human-like lipoprotein metabolism (i.e., high triglycerides, LDL and VLDL, low HDL) and accelerated atherosclerosis development (99). This evidence concerns the gene GLP1R and atherosclerosis.